Aethlon Medical to Participate in the IN3 Medical Device 360 Summit

-Company to Hold Second Quarter Fiscal 2016 Investor Call on November 16th-

SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that Jim Joyce, Chairman and CEO, will be presenting at the IN3 Medical Device 360 Summit Conference in San Francisco, CA at 2:50 p.m. ET (11:50 a.m. PT) on Wednesday, November 11, 2015.  The conference is not being webcast.

Aethlon Hemopurifier.

Also, as a reminder, the Company will host its Second Quarter Fiscal 2016 investor conference call and audio webcast on Monday, November 16, 2015 at 4:30 p.m. Eastern Time.

The call and audio webcast will follow the release of fiscal 2016 second quarter results.  A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website,

Interested parties can also access the archived replay of Aethlon Medical's First Quarter Fiscal 2016 investor conference call webcast at in the investor relations section under events & presentations.

Conference Call Details

What: Aethlon's Second Quarter Fiscal 2016 Investor Conference Call and Webcast

Date: Monday, November 16, 2015

Time: 4:30 p.m. Eastern Time

Live call: 412-902-6510

International: 877-270-2148

Audio Replay: 412-317-0088

Passcode: 10075367

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at or you can connect with us on Twitter, LinkedIn, Facebook and Google+.


James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000

Jim Frakes
Chief Financial Officer
858.459.7800 x300  

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc

Photo -


To view the original version on PR Newswire, visit:

SOURCE Aethlon Medical, Inc.